Yao Jiacheng, Zhu Feng, Feng Yikun, Gu Chen, Wang Tianyu, Li Xinyu, Yang Hao, Hu Xiamin, Bonnet Pierre-Antoine, Meng Xiangguo
Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Faculty of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Molecules. 2025 Apr 18;30(8):1827. doi: 10.3390/molecules30081827.
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. The difficulty in early diagnosis, combined with the tendency for tumor invasion and metastasis, creates significant challenges for current therapeutic approaches. Additionally, the pharmaceutical agents currently used to treat NSCLC often come with severe side effects and can lead to drug resistance. As a result, there is an urgent need to develop new therapeutic agents with fewer side effects that can effectively overcome resistance mechanisms. Flavonoids, a prominent class of natural compounds, have shown promise in preventing and treating various cancers. By structurally optimizing flavonoids, it is possible to enhance their anticancer activity and improve their pharmacokinetic properties. This article reviews the different mechanisms of action and structure-activity relationships (SARs) of flavonoid derivatives in treating NSCLC, aiming to provide a scientific foundation for developing new therapeutic agents.
非小细胞肺癌（NSCLC）是全球癌症相关死亡的主要原因。早期诊断的困难，加上肿瘤侵袭和转移的倾向，给当前的治疗方法带来了重大挑战。此外，目前用于治疗NSCLC的药物往往伴有严重的副作用，并可能导致耐药性。因此，迫切需要开发副作用较少且能有效克服耐药机制的新型治疗药物。黄酮类化合物是一类重要的天然化合物，在预防和治疗各种癌症方面已显示出前景。通过对黄酮类化合物进行结构优化，可以增强其抗癌活性并改善其药代动力学性质。本文综述了黄酮类衍生物在治疗NSCLC中的不同作用机制和构效关系（SARs），旨在为开发新型治疗药物提供科学依据。
